Purpose
To determine whether the risk of coronary events attributable to atherosclerosis of the coronary arteries can be reversed by
elevation of high-density lipoprotein (HDL) cholesterol and reduction of triglycerides
References
Goldbourt U, et al & Mandelzweig L: Rationale and design of a secondary prevention trial of increasing serum
high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic
heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993, 71: 909-915.
The Bezafibrate Infarction Prevention (BIP) Study Group: Lipids and lipoproteins in symptomatic coronary heart disease.
Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. Circulation 1992,
86:839-848.
Barasch E, et al & Goldbourt U: Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients.
The Bezafibrate Infarction Prevention (BIP) study. J Clin Epidemiol 1995, 48:757-165. |
Farmacêutica